Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer - A large nested case-control study within the JANUS cohort in Norway

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 197-206

  De Vogel, Stefan ^a   Ulvik, Arve ^b   Meyer, Klaus ^b   Ueland, Per Magne ^a,c   Nygård, Ottar ^a,c   Vollset, Stein Emil ^a,d   Tell, Grethe S ^a   Gregory, Jesse F ^e   Tretli, Steinar ^f   Bjørge, Tone ^a,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b BEVITAL AS   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e UNIVERSITY OF FLORIDA   (United States)

^f CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

case control study; choline oxidation pathway; population based; prostate cancer risk; sarcosine

Indexed keywords

BETAINE; CARBON; CHOLINE; DIMETHYLGLYCINE; GLYCINE; SARCOSINE; SERINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER RISK; CARBON BALANCE; CASE CONTROL STUDY; CHOLINE OXIDATION PATHWAY; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NORWAY; OXIDATION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION;

CASE-CONTROL STUDY; CHOLINE OXIDATION PATHWAY; POPULATION-BASED; PROSTATE CANCER RISK; SARCOSINE;

BETAINE; CASE-CONTROL STUDIES; CHOLINE; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; GLYCINE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NORWAY; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; SARCOSINE; SERINE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885947997     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28347     Document Type: Article

References (43)

1. Ulrich CM, Grady WM,. Linking epidemiology to epigenomics-where are we today? Cancer Prev Res (Phila) 2010; 3: 1505-8.
2. Ueland PM,. Choline and betaine in health and disease. J Inherit Metab Dis 2011; 34: 3-15.
3. Ueland PM, Midttun O, Windelberg A, et al. Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry. Clin Chem Lab Med 2007; 45: 1737-45.
4. Alonso-Aperte E, Gonzalez MP, Poo-Prieto R, et al. Folate status and S-adenosylmethionine/S-adenosylhomocysteine ratio in colorectal adenocarcinoma in humans. Eur J Clin Nutr 2008; 62: 295-8.
5. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
6. Collin SM, Metcalfe C, Refsum H, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1632-42.
7. Hultdin J, Van Guelpen B, Bergh A, et al. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer 2005; 113: 819-24.
8. Johansson M, Appleby PN, Allen NE, et al. Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev 2008; 17: 279-85.
9. Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009; 101: 432-5.
10. Qin X, Cui Y, Shen L, et al. Folic acid supplementation and cancer risk: a meta-analysis of randomized controlled trials. Int J Cancer 2013; 133: 1033-42.
11. Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals. Lancet 2013;;381: 1029-3.
12. Johansson M, Van Guelpen B, Vollset SE, et al. One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites. Cancer Epidemiol Biomarkers Prev 2009; 18: 1538-43.
13. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-14.
14. Cao DL, Ye DW, Zhu Y, et al. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis 2011; 14: 166-72.
15. Jentzmik F, Stephan C, Lein M, et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011; 185: 706-11.
16. Jentzmik F, Stephan C, Miller K, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010; 58: 12-18; discussion 20-1.
17. Stabler S, Koyama T, Zhao Z, et al. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One 2011; 6: e22486.
18. Janus Serum Bank. Available at: http://www.kreftregisteret.no/en/ Research/Janus-Serum-Bank/ (Assessed 1 November 2012).
19. Metabolites and vitamins. Available at: http://www.bevital.no/ (Assessed 1 November 2012).
20. Gislefoss RE, Grimsrud TK, Morkrid L,. Long-term stability of serum components in the Janus Serum Bank. Scand J Clin Lab Invest 2008; 68: 402-9.
21. Windelberg A, Arseth O, Kvalheim G, et al. Automated assay for the determination of methylmalonic acid, total homocysteine, and related amino acids in human serum or plasma by means of methylchloroformate derivatization and gas chromatography-mass spectrometry. Clin Chem 2005; 51: 2103-9.
22. Hannisdal R, Svardal A, Ueland PM,. Measurement of folate in fresh and archival serum samples as p-aminobenzoylglutamate equivalents. Clin Chem 2008; 54: 665-72.
23. Hannisdal R, Gislefoss RE, Grimsrud TK, et al. Analytical recovery of folate and its degradation products in human serum stored at -25 degrees C for up to 29 years. J Nutr 2010; 140: 522-6.
24. Hustad S, Eussen S, Midttun O, et al. Kinetic modeling of storage effects on biomarkers related to B vitamin status and one-carbon metabolism. Clin Chem 2012; 58: 402-10.
25. Meyer K, Fredriksen A, Ueland PM,. High-level multiplex genotyping of polymorphisms involved in folate or homocysteine metabolism by matrix-assisted laser desorption/ionization mass spectrometry. Clin Chem 2004; 50: 391-402.
26. Ulrich CM, Neuhouser M, Liu AY, et al. Mathematical modeling of folate metabolism: predicted effects of genetic polymorphisms on mechanisms and biomarkers relevant to carcinogenesis. Cancer Epidemiol Biomarkers Prev 2008; 17: 1822-31.
27. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46.
28. Meyer TE, Fox SD, Issaq HJ, et al. A reproducible and high-throughput HPLC/MS method to separate sarcosine from alpha- and beta-alanine and to quantify sarcosine in human serum and urine. Anal Chem 2011; 83: 5735-40.
29. Balassiano K, Lima S, Jenab M, et al. Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett 2011; 311: 85-95.
30. Vineis P, Chuang SC, Vaissiere T, et al. DNA methylation changes associated with cancer risk factors and blood levels of vitamin metabolites in a prospective study. Epigenetics 2011; 6: 195-201.
31. Davis SR, Quinlivan EP, Shelnutt KP, et al. Homocysteine synthesis is elevated but total remethylation is unchanged by the methylenetetrahydrofolate reductase 677C->T polymorphism and by dietary folate restriction in young women. J Nutr 2005; 135: 1045-50.
32. Reed MC, Nijhout HF, Neuhouser ML, et al. A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. J Nutr 2006; 136: 2653-61.
33. Heil SG, Van der Put NM, Waas ET, et al. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 2001; 73: 164-72.
34. Collin SM, Metcalfe C, Zuccolo L, et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2009; 18: 2528-39.
35. Wang L, Lu J, An J, et al. Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer: a case-control analysis. Lung Cancer 2007; 57: 143-51.
36. Kelemen LE, Sellers TA, Schildkraut JM, et al. Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res 2008; 68: 2498-506.
37. Lamers Y, Williamson J, Ralat M, et al. Moderate dietary vitamin B-6 restriction raises plasma glycine and cystathionine concentrations while minimally affecting the rates of glycine turnover and glycine cleavage in healthy men and women. J Nutr 2009; 139: 452-60.
38. Huang YC, Lee CM, Chen M, et al. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 2007; 13: 1412-20.
39. Song YH, Shiota M, Kuroiwa K, et al. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol 2011; 24: 1272-80.
40. de Vogel S, Ulvik A, Meyer K, et al. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk-a Norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. Int J Epidemiol 2013; 42: 201-10.
41. Hsing AW, Sakoda LC, Chua S, Jr,. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: s843-s857.
42. Ulvik A, Midttun O, Pedersen ER, et al. Association of plasma B-6 vitamers with systemic markers of inflammation before and after pyridoxine treatment in patients with stable angina pectoris. Am J Clin Nutr 2012; 95: 1072-8.
43. Kamaura M, Nishijima K, Takahashi M, et al. Lifestyle modification in metabolic syndrome and associated changes in plasma amino acid profiles. Circ J 2010; 74: 2434-40.